<DOC>
	<DOCNO>NCT00429871</DOCNO>
	<brief_summary>The combination docetaxel+epirubicin highly effective well tolerate first line treatment patient metastatic breast cancer ( MBC ) . Capecitabine active drug woman MBC pretreated taxane anthracycline . Docetaxel increase intracellular level thymidilate phosphorylase thus synergistic capecitabine . The combination docetaxel plus capecitabine highly active superior docetaxel monotherapy woman MBC pretreated anthracycline</brief_summary>
	<brief_title>Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine Metastatic Breast Cancer</brief_title>
	<detailed_description>This trial compare efficacy docetaxel plus epirubicin versus docetaxel plus capecitabine combination first line treatment woman MBC</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Histologically cytologically confirm metastatic breast adenocarcinoma . No previous chemotherapy treatment metastatic disease . No previous anthracycline treatment except adjuvant therapy least one year . Age 1975 year old Presence measurable disease Performance status 02 ( WHO ) Adequate cardiac function ( LVEF &gt; 50 % ) without recent ( within 6 month ) history myocardial infraction and/or unstable uncontrolled angina . Adequate bone marrow ( absolute neutrophil count &gt; 1500/mm3 , platelet count &gt; 100.000/mm3 , hemoglobin &gt; 10gr/mm3 ) , liver ( bilirubin &lt; 1.5 time upper limit normal SGOT/SGPT &lt; 2 time upper limit normal ) renal function ( creatinine &lt; 2mg/dl ) . No previous radiotherapy 25 % marrowcontaining bone . Written inform consent Active brain metastasis . Psychiatric illness social situation would preclude study compliance Other concurrent uncontrolled illness . Other invasive malignancy within past 5 year except nonmelanoma skin cancer . Positive pregnancy premenopausal woman . Concurrent antineoplastic treatment e.g . hormonal therapy</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Metastatic breast cancer ;</keyword>
	<keyword>First line chemotherapy ;</keyword>
	<keyword>Docetaxel ;</keyword>
	<keyword>Epirubicin ;</keyword>
	<keyword>Capecitabine</keyword>
</DOC>